Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CervoMed Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CRVO
Nasdaq
2834
www.cervomed.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CervoMed Inc.
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
- Nov 16th, 2026 2:02 pm
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
- Nov 9th, 2026 5:30 am
Agenus (AGEN) Q3 Earnings Meet Estimates
- Nov 5th, 2026 5:00 pm
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
- Oct 29th, 2026 5:30 am
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
- Oct 12th, 2026 5:30 am
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
- Sep 28th, 2026 5:30 am
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
- Sep 22nd, 2026 5:30 am
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
- Sep 10th, 2026 5:30 am
CervoMed to Participate in September Investor Conferences
- Sep 8th, 2026 5:30 am
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
- Aug 5th, 2026 5:30 am
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
- Aug 4th, 2026 3:15 am
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
- Jul 14th, 2026 5:30 am
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
- Jul 9th, 2026 5:30 am
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
- Jul 6th, 2026 5:30 am
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- Jun 22nd, 2026 2:05 pm
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally
- Jun 18th, 2026 11:55 am
Top Midday Gainers
- Jun 18th, 2026 11:32 am
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- Jun 18th, 2026 10:35 am
CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)
- Jun 18th, 2026 8:08 am
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
- Jun 18th, 2026 5:00 am
Scroll